Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial: a single-arm, multicentre, phase 2 trial
Uloženo v:
| Název: | Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial: a single-arm, multicentre, phase 2 trial |
|---|---|
| Autoři: | Hunger S. P., Tran T. H., Saha V., Devidas M., Valsecchi M. G., Gastier-Foster J. M., Cazzaniga G., Reshmi S. C., Borowitz M. J., Moorman A. V., Heerema N. A., Carroll A. J., Martin-Regueira P., Loh M. L., Raetz E. A., Schultz K. R., Slayton W. B., Cario G., Schrappe M., Silverman L. B., Biondi A. |
| Zdroj: | Hunger, S P, Tran, T H, Saha, V, Devidas, M, Valsecchi, M G, Gastier-Foster, J M, Cazzaniga, G, Reshmi, S C, Borowitz, M J, Moorman, A V, Heerema, N A, Carroll, A J, Martin-Regueira, P, Loh, M L, Raetz, E A, Schultz, K R, Slayton, W B, Cario, G, Schrappe, M, Silverman, L B & Biondi, A 2023, 'Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122) : a single-arm, multicentre, phase 2 trial', The Lancet. Haematology, vol. 10, no. 7, pp. e510-e520. https://doi.org/10.1016/S2352-3026(23)00088-1 |
| Informace o vydavateli: | Elsevier BV, 2023. |
| Rok vydání: | 2023 |
| Témata: | Imatinib Mesylate/therapeutic use, Male, Neoplasm, Residual, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Dasatinib, Antineoplastic Combined Chemotherapy Protocols, Child, Female, Humans, Imatinib Mesylate, Philadelphia Chromosome, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Treatment Outcome, 3. Good health, Residual, Neoplasm, Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy, Dasatinib/adverse effects |
| Popis: | The outcome of children with Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukaemia significantly improved with the combination of imatinib and intensive chemotherapy. We aimed to investigate the efficacy of dasatinib, a second-generation ABL-class inhibitor, with intensive chemotherapy in children with newly diagnosed Ph-positive acute lymphoblastic leukaemia.CA180-372/COG AALL1122 was a joint Children's Oncology Group (COG) and European intergroup study of post-induction treatment of Ph-positive acute lymphoblastic leukaemia (EsPhALL) open-label, single-arm, phase 2 study. Eligible patients (aged >1 year to |
| Druh dokumentu: | Article |
| Popis souboru: | application/pdf |
| Jazyk: | English |
| ISSN: | 2352-3026 |
| DOI: | 10.1016/s2352-3026(23)00088-1 |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/37407142 https://research.manchester.ac.uk/en/publications/2f53f33d-cfb7-4023-a496-e19f17537e42 https://doi.org/10.1016/S2352-3026(23)00088-1 https://hdl.handle.net/10281/473023 https://doi.org/10.1016/S2352-3026(23)00088-1 |
| Rights: | Elsevier TDM |
| Přístupové číslo: | edsair.doi.dedup.....75c45e509057b04edf141135cb85e045 |
| Databáze: | OpenAIRE |
Nájsť tento článok vo Web of Science | Abstrakt: | The outcome of children with Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukaemia significantly improved with the combination of imatinib and intensive chemotherapy. We aimed to investigate the efficacy of dasatinib, a second-generation ABL-class inhibitor, with intensive chemotherapy in children with newly diagnosed Ph-positive acute lymphoblastic leukaemia.CA180-372/COG AALL1122 was a joint Children's Oncology Group (COG) and European intergroup study of post-induction treatment of Ph-positive acute lymphoblastic leukaemia (EsPhALL) open-label, single-arm, phase 2 study. Eligible patients (aged >1 year to |
|---|---|
| ISSN: | 23523026 |
| DOI: | 10.1016/s2352-3026(23)00088-1 |